Today, physicians are able to target the unique nature of an individual patient’s tumor by matching treatments at the molecular level, resulting in improved outcome.

Already in 2011, a study from MD Anderson Cancer Center found that patients with advanced cancers treated with the traditional or standard of care, which is based on their type or origin of cancer rather than their DNA tumor profile, had a mere 5% response rate to their treatment.

The same study found that when patients with metastatic cancers were treated using a personalized approach, matching them at the molecular level, there was a 27% response rate.This was the beginning of personalized medicine using DNA. OmiCure™ goes one step further using RNA and it is available now.

Based on your personal results, your oncologist may propose a targeted therapy.

Alternatively, with the help of OmiCure™, the physician may avoid using a therapy which may not have the intended efficacy for you. This will prevent unnecessary adverse events from an ineffective therapy.

Using all information at hand, the oncologist may propose to continue the same therapy in the same oncology center, using the standard of care, or to have access to experimental therapies through your participation in clinical trials for these therapies.

OmiCure™ cannot determine whether a specific therapy is the right one for treatment, or predict the response of a specific patient to any specific therapy. The OmiCure™ report is not a source of medical advice for a patient or to have patients make treatment decisions on their own. Instead, information in the OmiCure™ report will exclusively guide discussions between a patient and his or her oncologist